AFC-HD AMS Life Science Co., Ltd. provided earnings guidance for the year ending August 2023. For the period, the company expects net sales of ¥24,741 million, Operating profit of ¥1,481 million, and Profit attributable to owners of the parent of ¥687 million or ¥48.82 basic per share.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
906 JPY | +0.11% | 0.00% | +13.25% |
1st Jan change | Capi. | |
---|---|---|
+13.25% | 80.45M | |
+9.79% | 7.89B | |
+2.60% | 7.2B | |
-2.68% | 5.75B | |
-8.03% | 3.64B | |
-14.39% | 3.42B | |
-15.43% | 1.16B | |
-28.11% | 1.1B | |
+5.08% | 906M | |
-16.12% | 857M |
- Stock Market
- Equities
- 2927 Stock
- News AFC-HD AMS Life Science Co., Ltd.
- AFC-HD AMS Life Science Co., Ltd. Provides Earnings Guidance for the Year Ending August 2023